Regulators of mammalian Hippo pathway in cancer
详细信息 查看全文
- 作者：Angela M. Liu ; Kwong-Fai Wong ; Xiaoou Jiang ; Yiting Qiao ; John M. Luk
- 关键词：BMP ; bone morphogenetic protein ; HCC ; hepatocellular carcinoma ; LATS1/2 ; large tumor suppressor 1/2 ; MST1/2 ; mammalian sterile 20-like kinase 1/2 ; RASSF1A ; Ras-association domain family 1 isoform A ; SAV1 ; Salvador ; TGF-¦Â ; transforming growth factor-beta
- 刊名：Biochimica et Biophysica Acta (BBA)/Reviews on Cancer
- 出版年：2012
- 出版时间：December, 2012
- 年：2012
- 卷：1826
- 期：2
- 页码：357-364
- 全文大小：712 K
文摘
Hippo pathway, originally discovered in Drosophila, is responsible for organ size control. The pathway is conserved in mammals and has a significant role in restraining cancer development. Regulating the Hippo pathway thus represents a potential therapeutic approach to treat cancer, which however requires deep understanding of the targeted pathway. Despite our limited knowledge on the pathway, there are increasing discoveries of new molecules that regulate and modulate the Hippo downstream signaling particularly in various solid malignancies, from extracellular stimuli or via pathway crosstalk. Herein, we discuss the roles of newly identified and key regulators that connect with core components (MST1/2, LATS1/2, SAV1, and MOB1) and downstream effector (YAP) in the Hippo pathway having an important role in cancer development and progression. Understanding of the mammalian Hippo pathway regulation may shed new insights to allow us selecting the right oncogenic targets and designing effective drugs for cancer treatments.